U.S. markets closed

Allena Pharmaceuticals, Inc. (ALNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2100-0.0100 (-0.82%)
At close: 4:00PM EDT

Allena Pharmaceuticals, Inc.

One Newton Executive Park
Suite 202
Newton, MA 02462
United States
617 467 4577

Full Time Employees29

Key Executives

NameTitlePayExercisedYear Born
Dr. Alexey L. MargolinCo-Founder & Chairman427.95kN/A1953
Dr. Louis BrennerPres, CEO & Director507.28kN/A1970
Mr. Edward J. WholihanChief Financial Officer387.03kN/A1960
Mr. Robert GallottoCo-Founder & Strategic AdviserN/AN/A1965
Mr. Hugh WightSr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.

Corporate Governance

Allena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.